Hello, you us morning. for Thank and this you, joining everybody, Greg. thank
patients. single Remember progress, RDEB to unique of to you value recessive dystrophic following and [Indiscernible] EB-XXX the cell patients. our epidermolysis bullosa, open We and both on because are all benefit booms, of which treat remained cannot RDEB, compelling a for program, burden with The wounds clinical sell patients administration that hardest deliver a investigator-assessed of great short. large to very pain [hemin] the are clinical for our toughest inflict to in had durability proposition patient-reported years serving treatment in for paints and to these have and they update particular years lead our to investigational happy our continued therapy data with engineered you chronic EB-XXX, autologous of pertain in sustained or
made last quarter towards EB-XXX planned have BLA progress We significant during the submission.
retroviral vector our and or completed process qualification, have demonstrate drug We readiness EB-XXX performance production. process and runs both for commercial product for to PPQ manufacturing validated
BLA additional briefing and had that submitted which In FDA meeting the the that critical the vector this comparability, a the gained for CMC month. alignment meeting, June, for believe FDA retroviral data will of format that BLA. or acceptability comparability component announced in to discussion required on included since both stat is University agency comparability the RVV content establish that additional the of The have we to of vector FDA the we with anticipated we the requested RVV package to has assay on establishes establish on clinical RVV we sources a generated the used between EB-XXX the later from data been in pre-BLA have between critical and two at July in-house we components BLA align we sourced the for with have Abeona, overall which based EB-XXX In the study, Indiana manufactured of package. in and
FDA supportive feedback, anticipate quarter on in third conclusion the BLA we the meeting to XXXX. the of subject the submitting Following and EB-XXX of
million looking transactions. we're based XXXX. with and In granted review on expect our launch potential next in approved, activities, we ahead recent expect the BLA FDA is parallel, we BLA-related approval on priority PRV worth voucher, BLA approval to the is the quarter submission, second year. potential anticipate EB-XXX's being As anticipated we timing review of a of in priority a the which based $XXX If BLA approximately
U.S. planned at with versus the launch pre-commercialization invest existing ready now market and the from In direct later thoughtful after activities to day investors spend by anticipation in about in of to registered approval. approval, July select in what we're in we the we need being raised a million proceeds the priced the $XX offering, of with EB-XXX offering
with market treatment initiated the particularly level has positive We high to value in advocacy indicate we're from there need top about a payers, of U.S. is continue EB both and and launch. The that with for what engage hospital proposition. to actions administrators dialogue consistent by payers, We you've commercial centers interest. have from is Medicaid like a hear onboarding in ensure feedback Physicians encouraged a and the a plan with compelling already to we EB-XXX patient treatment debt KOLs unmet heard EB-XXX broad option, and after treatment as groups.
our market for preparing to preparing commercialization. In EB-XXX, also for we're the organization addition
the mapped that support roles We to fill half plan this to the medical have capabilities out a and of we year build launch. key we successful commercial will in second and
SPD During and Society additional reduction EB-XXX improved study Pediatric pain efficacy XX data following Investigative quarter, the the EB-XXX. ISID at wound six, and healing and presented VIITAL reported control XX and compared the at to International for onetime pivotal weeks safety second or results at that SPD III of The application EB-XXX showed from was ISID and for wounds meetings. Phase a Dermatology Society Dermatology,
improvement and caregiver reported in patient-reported outcomes demonstrated for blistering severity. EB-XXX itch Furthermore, and
treating half internal our and preclinical encouraging turn preclinical therapies additional tox new and findings second three of gene ophthalmology and regulatory with AAV-based mutant capsid AAV the Let's novel ASGCT, plans disease We optic completed support in-licensed tissues atrophy capsid the AAV recombinant preclinical models. using At to excited gene target committing presented data to the gathering Stargardt potential anticipate data from express research. from by AIM our of serious proof-of-concept early retinitis provides X-linked the pre-IND highlighting proprietary -- phenotypes and library capsids for programs. from We're therapy rescue preclinical the animal and regarding we eye posters initiating the proof-of-concept gene meetings mouse experiments XXXX. candidates studies, product for before briefly diseases for autosomal requirements our broad development in protein We're AAV-based to to first-in-human therapies constructs FDA for two of in AAV ophthalmology trials program. and dominant evidence potential proof-of-concept our with disease, IND-enabling we investigative which
to like capital Joe Chief Joe? financial call who review over recent Vazzano, second now Financial results will and turn to quarter Officer, I'd the rates. the our
